

Accuracy, Safety, and Reliability of Novel Phase I Designs—Letter

Nolan A. Wages¹ and Thomas M. Braun²



A recently published review (1) of the accuracy, safety, and reliability of novel phase I methods concluded that the Bayesian Optimal Interval (BOIN; ref. 2) method does not suffer from the issue of "irrational" dose assignment. This property is defined by the authors as failing to deescalate the dose when 2 of 3 or ≥ 3 of 6 patients had dose-limiting toxicities (DLT) at a dose. This letter examines the author's definition of irrational dose assignment in a simulated trial example using the BOIN method. We generated DLT outcomes under an assumed set of true DLT probabilities (0.18, 0.25, 0.32, 0.36, 0.60, 0.69; Scenario 2 in Supplementary Table S2 of Zhou and colleagues; ref. 1) for a trial of $n = 36$ patients in cohorts of size 1. The target DLT rate is 25%, which yields dose escalation and deescalation boundaries of 19.7% and 29.8%, respectively. The allocation decisions of the BOIN method for the simulated trial are reported in Fig. 1. Note that patient 15 is the third of 6 patients to have a DLT with dose 3. Thus, the dose assignment for patient 16 is deescalated to dose 2, a decision that is classified as "rational" by the authors (1). However, the BOIN method recommends returning to dose level 3 with patient 17 immediately after a DLT is observed at dose level 2 in patient 16. In fact, no matter what DLT outcome was observed for patient 16, the observed DLT rate at dose level 2, either 0 of 6 or 1 of 6, would guarantee that the BOIN method would return to dose level 3 for patient 17. Therefore, the




Figure 1.

Simulated trial example of the Bayesian optimal interval design for $n = 36$ patients under Scenario 2 in Supplementary Table S2 of Zhou and colleagues (1). The design escalates if the observed DLT rate at the current dose level $\leq 19.7\%$. The design deescalates if the observed DLT rate at the current dose level is $\geq 29.8\%$. Otherwise, the current dose level is retained.

information obtained from the participation of patient 16 in the study does not contribute to the dose assignment algorithm for patient 17. Overall, data observed for 8 of 36 (22%) patients accrued to the study (patients 9, 13, 16, 17, 19, 21, 23, and 30) do not inform the dosing decision for the following patient accrued to the study. It is not clinically sensible to view as irrational the failing to deescalate when ≥ 3 of 6 patients experienced DLTs, but then allow, as rational, returning to that dose when the very next patient has a DLT at the next lowest dose level. While this simulated trial constitutes only a single example of a behavior of the BOIN method that would not be clinically acceptable, we hope that it will encourage researchers to take a closer look at in-trial behavior of new phase I methods.

Disclosure of Potential Conflicts of Interest

No potential conflicts of interest were disclosed.

Received July 2, 2018; revised August 28, 2018; accepted September 5, 2018; published first November 1, 2018.

¹Division of Translational Research & Applied Statistics, Department of Public Health Sciences, University of Virginia, Charlottesville, Virginia. ²Department of Biostatistics, School of Public Health, University of Michigan, Ann Arbor, Michigan.

Corresponding Author: Nolan A. Wages, Division of Translational Research & Applied Statistics, University of Virginia, Public Health Sciences, P.O. Box 800717, Charlottesville, VA 22908-0717. Phone: 434-924-8222; Fax: 434-243-5787; E-mail: nwages@virginia.edu

doi: 10.1158/1078-0432.CCR-18-2090

©2018 American Association for Cancer Research.

References

- Zhou H, Yuan Y, Nie L. Accuracy, safety, and reliability of novel phase I trial designs. *Clin Cancer Res* 2018.
- Yuan Y, Hess KR, Hilsenbeck SG, Gilbert MR. Bayesian optimal interval design: a simple and well-performing design for phase I oncology trials. *Clin Cancer Res* 2016;22:4291–301.

Clinical Cancer Research

Accuracy, Safety, and Reliability of Novel Phase I Designs—Letter

Nolan A. Wages and Thomas M. Braun

Clin Cancer Res 2018;24:5482.

Updated version Access the most recent version of this article at:
<http://clincancerres.aacrjournals.org/content/24/21/5482>

Cited articles This article cites 1 articles, 1 of which you can access for free at:
<http://clincancerres.aacrjournals.org/content/24/21/5482.full#ref-list-1>

Citing articles This article has been cited by 1 HighWire-hosted articles. Access the articles at:
<http://clincancerres.aacrjournals.org/content/24/21/5482.full#related-urls>

E-mail alerts [Sign up to receive free email-alerts](#) related to this article or journal.

Reprints and Subscriptions To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions To request permission to re-use all or part of this article, use this link
<http://clincancerres.aacrjournals.org/content/24/21/5482>.
Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.